AQP1 and Schnyder corneal dystrophy: Combined application of a selective AQP1 ion channel blocker AqB011 (80 μM) with a selective hemoglobin modifying agent 5-NMFC (2.5 mM) increased anti-sickling effectiveness in red blood cells from human SCD patients.